Equities

Science in Sport PLC

Science in Sport PLC

Actions
Consumer Staples Food Producers
  • Price (GBX)31.50
  • Today's Change2.50 / 8.62%
  • Shares traded113.58k
  • 1 Year change-59.09%
  • Beta0.9702
Data delayed at least 20 minutes, as of Aug 10 2022 17:08 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Science in Sport plc is a United Kingdom-based sports nutrition company. The Company develops, manufactures, and markets nutrition products for professional athletes, sports and fitness enthusiasts and the active lifestyle community. The Company has two brands, PhD Nutrition, a premium active-nutrition brand targeting the active lifestyle community, and SiS, an endurance nutrition brand among elite athletes and professional sports teams. The PhD Nutrition product range consists of protein powders, bars and supplements, including the high protein, low sugar product, PhD Smart. The Company's SiS product range consists of energy powders, isotonic gels, energy bars and supplements. The two brands sell through the Company's phd.com and scienceinsport.com digital platforms, third-party online sites, including Amazon and Tmall, and extensive retail distribution in the United Kingdom and internationally, including major supermarkets, high street chains and specialist sports retailers.

  • Revenue in GBP (TTM)62.54m
  • Net income in GBP-6.82m
  • Incorporated2013
  • Employees218.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fusion Antibodies PLC4.70m-3.01m24.97m54.00--5.86--5.31-0.1159-0.11590.18130.16380.68745.023.2687,055.55-44.04-21.34-50.93-24.7150.0347.45-64.07-36.643.57-166.880.0346--6.9322.97-315.93--59.14--
OptiBiotix Health PLC2.21m6.26m27.74m12.006.411.454.0311.940.04680.04680.02540.20620.13087.622.01184,410.8036.9919.8038.3420.8350.7655.24282.93187.406.24--0.0431--45.2850.347.91--2.29--
4d Pharma PLC522.00k-53.96m30.04m95.00--1.29--57.56-0.3361-0.33610.00310.12870.0133--0.19375,494.74-137.72-56.02-161.03-62.60-----10,337.17-11,690.925.16-157.990.2998---2.25---107.83---38.56--
Destiny Pharma PLC0.00-5.34m30.06m18.00--3.19-----0.0892-0.08920.000.12540.00----0.00-48.57-41.12-53.54-43.98------------0.00------1.32------
LungLife AI Inc159.97k-6.09m32.48m13.00--1.95--200.68-0.239-0.2390.00630.64620.0172--8.0512,305.24-65.47---153.60--50.77---3,806.60-----15.130.0386---4.68---53.84------
Tissue Regenix Group PLC22.15m-5.38m35.87m79.00--0.9692--1.66-0.0008-0.00080.00320.00540.41231.185.18280,381.40-10.41-21.22-11.23-23.2542.9446.54-25.25-66.702.83-5.950.1922---6.5159.1170.02--8.02--
Verici Dx Plc0.00-6.81m38.73m12.00--3.25-----0.0481-0.04810.000.0692------0.00--------------------0.00-------75.92------
OKYO Pharma Ltd0.00-3.91m38.91m6.00--5.02-----0.005-0.0050.000.00550.00----0.00-78.12---84.75-------------3,398.270.0162-------146.83------
Science in Sport PLC62.54m-6.82m40.34m218.00--0.9656--0.6923-0.0505-0.05050.46290.32620.91384.055.55286,876.20-9.96-9.41-12.46-11.3050.1349.61-10.90-11.801.14-45.820.2197--24.2138.56-294.50--46.77--
Skinbiotherapeutics PLC21.95k-1.93m40.76m7.00--9.61--1,821.37-0.0122-0.01220.00010.02650.0041--0.07683,135.71-35.72-31.36-37.68-33.1861.00---8,780.50--10.01-326.990.0297------4.47---3.79--
Venture Life Group PLC32.76m2.40m43.01m145.0019.920.56586.821.270.01650.01650.24480.58140.33382.213.30225,944.802.451.962.732.2839.5540.367.334.701.666.040.1482--8.9318.071.44--43.29--
Yourgene Health PLC27.56m-9.86m47.99m180.00--1.35--1.69-0.0137-0.01370.03820.04750.49723.263.81153,094.60-17.79-24.79-21.58-33.6960.2957.85-35.79-53.901.34-11.620.1345--10.0849.46-400.58--27.36--
Spectral MD Holdings Ltd12.41m-4.43m48.30m55.00--4.26--3.85-0.0583-0.05830.12370.0823------225,587.00--------46.03---27.39------0.00---12.33---538.47------
Celadon Pharmaceuticals PLC0.00-473.01k49.64m----0.9502-----0.0679-0.06790.000.8420.00-------7.68---7.72-----------------------171.05------
Synairgen plc0.00-48.66m53.36m24.00--1.46-----0.243-0.2430.000.18380.00----0.00-73.08-51.45-79.68-56.23-------1,325.615.81--0.00-------249.69--45.85--
C4X Discovery Holdings PLC5.71m-4.72m57.65m46.00--3.79--10.10-0.0207-0.02070.02510.06640.3055--9.62124,087.00-25.27-60.05-27.28-68.5397.3999.28-82.71-237.08---493.000.0192----82.4650.65---13.79--
Data as of Aug 10 2022. Currency figures normalised to Science in Sport PLC's reporting currency: UK Pound GBX

Institutional shareholders

74.22%Per cent of shares held by top holders
HolderShares% Held
Lombard Odier Asset Management (Europe) Ltd.as of 11 May 202219.48m14.01%
Aviva Investors Global Services Ltd.as of 23 Nov 202114.64m10.53%
Otus Capital Management Ltd.as of 23 Nov 202114.12m10.15%
BennBridge Ltd.as of 07 Apr 202211.77m8.46%
J.O. Hambro Capital Management Ltd.as of 30 Dec 202111.75m8.45%
River & Mercantile Asset Management LLPas of 23 Nov 20219.66m6.95%
AXA Investment Managers UK Ltd.as of 23 Nov 20215.77m4.15%
Sarasin & Partners LLPas of 23 Nov 20215.59m4.02%
Baillie Gifford & Co.as of 23 Nov 20215.23m3.76%
Schroder Investment Management Ltd.as of 23 Nov 20215.21m3.75%
More ▼
Data from 31 Mar 2022 - 02 Jul 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.